Changes in sinus opacification observed with DUPIXENT® and

placebo

DUPIXENT® significantly decreased LMK-CT scan score vs. placebo + INCS at week 24, with consistent results at week 521

29% improvement at week 24 (secondary endpoint) with DUPIXENT® (n=295, pooled DUPIXENT® arms) (-5.21 from baseline score 18.12) vs. 0.5% improvement with placebo (n=153) (-0.09 from baseline score 17.65) (LSM difference -5.13; 95% CI -5.80, -4.46)

Changes in LMK scores observed at week 52 were consistent with results observed at week 24.

CT scan images for illustrative purposes only

Baseline

CT scan showing a patient’s sinuses at baseline. Arrows point to areas of sinus opacification.

Week 52

CT scan showing a patient’s sinuses at week 52. Arrows point to the changes in sinus opacification.

Example of patient CT scan image. Not representative of all patients.

Lund-Mackay computed tomography scan (LMK-CT) score evaluates the opacification of each sinus using a 0 to 2 scale (0=normal; 1=partial opacification; 2=total opacification) deriving a maximum score of 12 per side and a total maximum of 24. Higher scores indicate more opacification; reduced score indicates improvement.

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

Freedom support program logo.

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300229E
Last updated: 06/2023

paab logo